Cambium Bio (ASX:CMB) Non Operating Income: A$0.82 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CMB Cambium Bio Ltd ASX:CMB
29 GF Score
Price A$0.43
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Non Operating Income?

Cambium Bio ASX:CMB 29 Non Operating Income is A$0.82 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 29/100. The stock has 4 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Cambium Bio's Non Operating Income for the six months ended in Dec. 2025 was A$0.45 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.82 Mil.

Cambium Bio Non Operating Income Related Terms

Cambium Bio Non Operating Income Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Non Operating Income Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.15 0.92

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 0.17 0.55 0.38 0.45
ASX:CMB
29GF Score
Cambium Bio Ltd ASX:CMB
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of A$0.82 Mil mean?
Cambium Bio (ASX:CMB) has a Non Operating Income of A$0.82 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Cambium Bio and its competitors.
Is Cambium Bio's Non Operating Income too high?
Cambium Bio's current Non Operating Income is A$0.82 Mil. Overall, Cambium Bio has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Non Operating Income compare to VRTX and REGN?
Cambium Bio's Non Operating Income of A$0.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Cambium Bio and its competitors. Cambium Bio's current Non Operating Income is A$0.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Non Operating Income of A$0.82 Mil. The current Non Operating Income is A$0.82 Mil. Cambium Bio's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Non Operating Income is A$0.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
29GF Score

Get the complete analysis for ASX:CMB

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.43
Price